Systematic Financial Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $77M | Buy |
407,114
+10,237
| +3% | +$1.79M | 1.76% | 5 |
|
|
2025
Q4 | $67.5M | Buy |
396,877
+2,536
| +0.6% | +$389K | 1.59% | 5 |
|
|
2025
Q3 | $52M | Sell |
394,341
-9,169
| -2% | -$1.1M | 1.26% | 15 |
|
|
2025
Q2 | $42.8M | Buy |
403,510
+16,607
| +4% | +$1.8M | 1.14% | 22 |
|
|
2025
Q1 | $48M | Buy |
386,903
+10,590
| +3% | +$1.38M | 1.37% | 9 |
|
|
2024
Q4 | $46.3M | Buy |
376,313
+92,336
| +33% | +$10.9M | 1.18% | 13 |
|
|
2024
Q3 | $31.6M | Buy |
283,977
+29,647
| +12% | +$3.25M | 0.81% | 38 |
|
|
2024
Q2 | $27.1M | Buy |
254,330
+13,651
| +6% | +$1.5M | 0.82% | 36 |
|
|
2024
Q1 | $29M | Buy |
240,679
+42,451
| +21% | +$5.2M | 0.81% | 41 |
|
|
2023
Q4 | $24.4M | Sell |
198,228
-7,546
| -4% | -$942K | 0.72% | 53 |
|
|
2023
Q3 | $26.6M | Sell |
205,774
-1,476
| -0.7% | -$197K | 0.86% | 35 |
|
|
2023
Q2 | $25.7M | Sell |
207,250
-3,439
| -2% | -$463K | 0.81% | 40 |
|
|
2023
Q1 | $30.8M | Buy |
210,689
+10,173
| +5% | +$1.5M | 1.01% | 20 |
|
|
2022
Q4 | $31.9M | Sell |
200,516
-1,080
| -0.5% | -$158K | 1.05% | 17 |
|
|
2022
Q3 | $26.9M | Sell |
201,596
-4,668
| -2% | -$710K | 0.98% | 18 |
|
|
2022
Q2 | $32.2M | Buy |
206,264
+4,967
| +2% | +$765K | 1.12% | 13 |
|
|
2022
Q1 | $31.3M | Buy |
201,297
+4,259
| +2% | +$618K | 0.98% | 23 |
|
|
2021
Q4 | $25.1M | Sell |
197,038
-6,109
| -3% | -$803K | 0.74% | 53 |
|
|
2021
Q3 | $26.5M | Buy |
203,147
+48,790
| +32% | +$7.37M | 0.82% | 45 |
|
|
2021
Q2 | $27.4M | Buy |
154,357
+24,635
| +19% | +$4.27M | 0.83% | 40 |
|
|
2021
Q1 | $21.3M | Buy |
129,722
+13,404
| +12% | +$2.21M | 0.78% | 48 |
|
|
2020
Q4 | $19.2M | Sell |
116,318
-5,698
| -5% | -$849K | 0.84% | 36 |
|
|
2020
Q3 | $17.4M | Sell |
122,016
-40,955
| -25% | -$5.08M | 0.95% | 28 |
|
|
2020
Q2 | $18M | Sell |
162,971
-2,176
| -1% | -$241K | 0.93% | 29 |
|
|
2020
Q1 | $16.5M | Buy |
165,147
+48,941
| +42% | +$6.33M | 1.01% | 21 |
|
|
2019
Q4 | $17.3M | Buy |
116,206
+9,928
| +9% | +$1.35M | 0.68% | 65 |
|
|
2019
Q3 | $13.6M | Buy |
106,278
+794
| +0.8% | +$106K | 0.61% | 74 |
|
|
2019
Q2 | $15M | Buy |
105,484
+56,326
| +115% | +$7.57M | 0.58% | 64 |
|
|
2019
Q1 | $7.03M | Sell |
49,158
-90,981
| -65% | -$11.9M | 0.24% | 134 |
|
|
2018
Q4 | $17.4M | Sell |
140,139
-3,077
| -2% | -$456K | 0.53% | 46 |
|
|
2018
Q3 | $24.1M | Buy |
143,216
+1,368
| +1% | +$235K | 0.58% | 33 |
|
|
2018
Q2 | $24.4M | Buy |
141,848
+29,446
| +26% | +$4.81M | 0.6% | 32 |
|
|
2018
Q1 | $17M | Buy |
+112,402
| New | +$16.5M | 0.38% | 88 |
|
|
2016
Q3 | – | Sell |
-3,016
| Closed | -$426K | – | 616 |
|
|
2016
Q2 | $426K | Buy |
3,016
+1,752
| +139% | +$258K | 0.01% | 553 |
|
|
2016
Q1 | $165K | Buy |
+1,264
| New | +$157K | ﹤0.01% | 567 |
|
|
2013
Q4 | – | Sell |
-616,202
| Closed | -$56.7M | – | 669 |
|
|
2013
Q3 | $56.7M | Sell |
616,202
-681,555
| -53% | -$55M | 0.45% | 74 |
|
|
2013
Q2 | $89.2M | Buy |
+1,297,757
| New | +$79.3M | 0.76% | 41 |
|
Other funds holding JAZZ
VPM
VCM
EC
Systematic Financial Management's JAZZ Position: Q1 2026 in Review
Systematic Financial Management increased its Jazz Pharmaceuticals (JAZZ) stake by 2.6% in Q1 2026, buying an estimated $1.79M and bringing the position to 407,114 shares worth $77M. The position accounts for 1.76% of the portfolio, ranked #5.
Systematic Financial Management first reported a position in JAZZ in Q2 2013 and has held it in 37 quarters since. The position peaked at $89.2M in Q2 2013. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Systematic Financial Management held 407,114 shares of Jazz Pharmaceuticals worth $77M as of Q1 2026.
- Systematic Financial Management bought 10,237 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.79M.
- Jazz Pharmaceuticals made up 1.76% of Systematic Financial Management's portfolio in Q1 2026, its #5 holding.
- Systematic Financial Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
- Systematic Financial Management's Jazz Pharmaceuticals position peaked at $89.2M in Q2 2013.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Systematic Financial Management's 13F filing for Q1 2026, filed 13 May 2026.